26 different customers representing North America, Asia and Europe33 oral presentations across four consecutive days69 scientific posters will be featured in a virtual…
SAN DIEGO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its 2024 Symposium, the quintessential event…
Preliminary Q4 2023 revenue expected to be between $10.4 and $10.7 million, which would represent an estimated increase of 27%…
WOBURN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biotechnology company dedicated to the development of gut-targeted,…
Data from at least 20 patients enrolled in dose expansion cohorts anticipated in the first half of 2024NOVATO, Calif., Jan.…
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced a publication outlining the addition of…
SAN DIEGO, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced significant upgrades to its pipeline for…
Key findings from prospective evaluation of 200 prenatal samples: Optical genome mapping (OGM) detected pathogenic structural variants (SVs) in 20.5%…
TEL AVIV, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical…
TARRYTOWN, NY / ACCESSWIRE / November 22, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused…